Unaudited Financial results for quarter and Nine months ended 31.12.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parmax Pharma reported weak unaudited results for Q3 FY26 and the nine months ended December 31, 2025. Revenue from operations fell to Rs. 4.33 crore in Q3 from Rs. 6.28 crore a year earlier, a drop of about 31%. For the nine months, revenue collapsed to Rs. 8.80 crore from Rs. 23.38 crore, nearly 62% lower year-on-year. The company posted a net loss of Rs. 73.19 lakh in Q3 (versus Rs. 39.45 lakh loss a year ago) and Rs. 3.57 crore loss for nine months (versus Rs. 59.92 lakh loss a year ago). Loss per share widened to Rs. 9.55 for nine months from Rs. 1.60 previously. The auditor flagged two issues: depreciation has not been charged on clean room and effluent treatment plants due to non-use, and an insurance claim of Rs. 3.5 crore related to a December 2023 fire is still pending submission.
Sharply falling revenue and widening losses signal serious operational stress, likely weighing on the stock. The pending insurance claim and unprovided depreciation add further uncertainty for shareholders about the true asset and earning position.